Skip to main content
. 2022 Dec 7;26:378. doi: 10.1186/s13054-022-04248-x

Table 1.

Baseline characteristics according to treatment assignment

Characteristics Total (n = 148) AMCPR (n = 74) Placebo (n = 74)
Patients characteristics
Age, year 77.0 (68.3–83.0) 77.5 (70.0–83.0) 77.0 (67.0–83.0)
Sex
 Male 100 (67.6) 47 (63.5) 53 (71.6)
 Female 48 (32.4) 27 (36.5) 21 (28.4)
Comorbidities
 Coronary artery syndrome 22 (14.9) 10 (13.5) 12 (16.2)
 Atrial fibrillation 7 (4.7) 3 (4.1) 4 (5.4)
 Chronic heart failure 5 (3.4) 2 (2.7) 3 (4.1)
 Stroke 9 (6.1) 4 (5.4) 5 (6.8)
 Hypertension 64 (43.2) 31 (41.9) 33 (44.6)
 Diabetes 49 (33.1) 25 (33.8) 24 (32.4)
 Pulmonary disease 14 (9.5) 3 (4.1) 11 (14.9)
 Neurologic disease 18 (12.2) 10 (13.5) 8 (10.8)
 Kidney disease 11 (7.4) 6 (8.1) 5 (6.8)
 Liver disease 2 (1.4) 1 (1.4) 1 (1.4)
 Cancer 21 (14.2) 9 (12.2) 12 (16.2)
Cardiac arrest characteristics
 Witnessed 92 (62.2) 47 (63.5) 45 (60.8)
 Bystander chest compression 91 (61.5) 46 (62.2) 45 (60.8)
 Prehospital AED 13 (8.8) 9 (12.2) 4 (5.4)
Initial rhythm
 Asystole 106 (71.6) 50 (67.6) 56 (75.7)
 Pulseless electrical activity 32 (21.6) 17 (23.0) 15 (20.3)
 Ventricular fibrillation a 9 (6.1) 6 (8.1) 3 (4.1)
Presumed arrest cause
 Cardiac 77 (52.7) 37 (50.7) 40 (54.8)
 Other medical 64 (43.8) 34 (46.6) 30 (41.1)
Prehospital low flow time, min 28.0 (23.0–34.0) 29.0 (25.0–33.3) 26.0 (21.0–34.0)
Time from ED arrival to
 Epinephrine administration, min 1.0 (1.0–2.0) 1.0 (1.0–3.0) 1.0 (0.0–2.0)
 Vasopressin or normal saline administration, min 4.0 (3.0–6.0) 5.0 (3.0–5.0) 4.0 (3.0–6.0)
Treatment after ROSC
 PCI 9 (6.1) 5 (6.8) 4 (5.4)
 TTM 34 (23.0) 16 (21.6) 18 (24.3)
 RRT 9 (6.1) 4 (5.4) 5 (6.8)

Data presented as number (percentage) and median (interquartile range)

AMCPR Augmented-Medication of CardioPulmonary Resuscitation; AED automated external defibrillator; ED emergency department; ROSC return of spontaneous circulation; PCI percutaneous coronary intervention; TTM target temperature management; RRT renal replacement therapy

aPatients with ventricular fibrillation at initial presentation which converted to pulseless electrical activity or asystole within 6 min (3 cycles) were included